Darolutamide Delays Metastasis in High-risk CRPC Patients, Phase 3 Trial Shows

Darolutamide Delays Metastasis in High-risk CRPC Patients, Phase 3 Trial Shows
Adding the androgen receptor inhibitor darolutamide to androgen deprivation therapy (ADT) extends by 22 months the time men with castration-resistant prostate cancer live without metastasis, without increasing the incidence of adverse events, results from a Phase 3 trial show. The treatment also extended survival, time to pain progression, time until chemotherapy was needed, and kept patients alive and progression-free for longer periods than ADT alone, researchers reported. Findings from the
Subscribe or to access all post and page content.